Overview

A Multicenter, Open-label Extension Study to Investigate the Long-term Safety of FAB122 in Patients With Amyotrophic Lateral Sclerosis

Status:
Recruiting

Trial end date:
2026-06-30

Target enrollment:

Participant gender:

Summary

A multicenter, open-label extension study to investigate the long-term safety of FAB122 in patients with Amyotrophic Lateral Sclerosis

Phase:

Phase 3

Details

Lead Sponsor:

Ferrer Internacional S.A.